Across TCGA pan-cancer cohorts, MIR137HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR137HG data layer compared with 18 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MIR137HG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR137HG expression acts as an unfavorable survival marker.
UCEC are the cancer types where MIR137HG Mutation most reproducibly stratifies survival.